Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

We recently showed that the outcome of multiple myeloma (MM) patients treated in the REPEAT study (evaluation of lenalidomide combined with low-dose cyclophosphamide and prednisone (REP) in lenalidomide-refractory MM) was markedly better than what has been described with cyclophosphamide-prednisone...

Descripción completa

Detalles Bibliográficos
Autores principales: Franssen, Laurens E., Nijhof, Inger S., Bjorklund, Chad C., Chiu, Hsiling, Doorn, Ruud, van Velzen, Jeroen, Emmelot, Maarten, van Kessel, Berris, Levin, Mark-David, Bos, Gerard M.J., Broijl, Annemiek, Klein, Saskia K., Koene, Harry R., Bloem, Andries C., Beeker, Aart, Faber, Laura M., van der Spek, Ellen, Raymakers, Reinier, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M., Thakurta, Anjan, Qian, Xiaozhong, Mutis, Tuna, van de Donk, Niels W.C.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188055/
https://www.ncbi.nlm.nih.gov/pubmed/30338042
http://dx.doi.org/10.18632/oncotarget.26131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188055/
https://www.ncbi.nlm.nih.gov/pubmed/30338042
http://dx.doi.org/10.18632/oncotarget.26131

Ejemplares similares